Sarepta Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Public

Established: 1980-01-01

Employees: 1.3K

Market Cap: $13.4B

Website: http://www.sarepta.com

Introduction: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Clinical Trials

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Genetic: delandistrogene moxeparvovec

First Posted Date: 2017-12-15

Last Posted Date: 2024-11-14

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 4

Registration Number: NCT03375164

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Eteplirsen

First Posted Date: 2017-07-17

Last Posted Date: 2021-12-09

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 15

Registration Number: NCT03218995

Locations: 🇧🇪
Universitair ziekenhuis Gent, Gent, Belgium
🇫🇷
Armand-Trousseau Hospital, Paris, France
🇮🇹
Site Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy

and more 1 locations

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Phase 1

Completed

Conditions: Dysferlinopathy

Interventions: Drug: rAAVrh74.MHCK7.DYSF.DV

First Posted Date: 2016-03-16

Last Posted Date: 2021-05-13

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 2

Registration Number: NCT02710500

Locations: 🇺🇸
Nationwide Children's Hosptial, Columbus, Ohio, United States

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Placebo
Drug: SRP-4045

First Posted Date: 2015-08-21

Last Posted Date: 2021-05-17

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 12

Registration Number: NCT02530905

Locations: 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase 3

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: SRP-4045
Drug: SRP-4053
Drug: Placebo

First Posted Date: 2015-07-16

Last Posted Date: 2024-12-16

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 228

Registration Number: NCT02500381

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇨🇿
University Hospital Brno, Brno, Czechia
🇫🇷
Reference Centre for Neuromuscular Diseases, Nantes, France

and more 72 locations

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy (DMD)

Interventions: Drug: eteplirsen

First Posted Date: 2015-04-17

Last Posted Date: 2021-01-25

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 33

Registration Number: NCT02420379

Locations: 🇺🇸
University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸
Rare Disease Research Center, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Atlanta, Atlanta, Georgia, United States

and more 10 locations

Phase I/II Study of SRP-4053 in DMD Patients

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: SRP-4053
Drug: Placebo

First Posted Date: 2014-12-08

Last Posted Date: 2020-10-19

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 39

Registration Number: NCT02310906

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇮🇹
Policlinico Universitario A Gemelli, Rome, Italy
🇫🇷
Institute de Myologie, Paris, France

and more 2 locations

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Phase 2

Completed

Conditions: Muscular Dystrophy, Duchenne

Interventions: Drug: Eteplirsen

First Posted Date: 2014-11-10

Last Posted Date: 2020-03-30

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT02286947

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 6 locations

Study of Eteplirsen in DMD Patients

Phase 3

Completed

Conditions: Duchenne Muscular Dystrophy (DMD)

Interventions: Drug: eteplirsen

First Posted Date: 2014-10-02

Last Posted Date: 2021-01-25

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 109

Registration Number: NCT02255552

Locations: 🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 34 locations

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

Phase 1

Completed

Conditions: Limb-Girdle Muscular Dystrophy, Type 2D

Interventions: Genetic: SRP-9004

First Posted Date: 2013-11-05

Last Posted Date: 2023-06-15

Lead Sponsor: Sarepta Therapeutics, Inc.

Target Recruit Count: 6

Registration Number: NCT01976091

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy